Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

BACKGROUND Aberrant accumulation of transition metals in the brain may have an early and important role in the pathogenesis of several neurodegenerative disorders, including Huntington disease (HD). OBJECTIVE To comprehensively evaluate and validate the distribution of metal deposition in the brain using advanced magnetic resonance imaging methods from the premanifest through symptomatic stages of HD. DESIGN Observational study. SETTING University imaging center. PARTICIPANTS Twenty-eight HD expanded gene carriers, 34 patients with symptomatic HD, and 56 age- and sex-matched healthy control subjects were included in the study. INTERVENTIONS Participants underwent magnetic resonance imaging for the quantification of the phase evolution of susceptibility-weighted images. MAIN OUTCOME MEASURES To verify the identity of the metals responsible for the changes in the phase evolution of the susceptibility signal in the brain and to assess correlations with systemic levels. Inductively coupled plasma mass spectrometry was used to measure transition metal concentrations in postmortem brains. RESULTS In the basal ganglia, progressive increases in the phase evolution were found in HD, beginning in premanifest individuals who were far from expected onset and increasing with proximity to expected onset and thereafter. Increases in the cerebral cortex were regionally selective and present only in symptomatic HD. Increases were verified by excessive deposition of brain iron, but a complex alteration in other transition metals was found. CONCLUSION An important and early role of altered metal homeostasis is suggested in the pathogenesis of HD.

[1]  S. Hersch,et al.  Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein* , 2011, The Journal of Biological Chemistry.

[2]  H. D. Rosas,et al.  Biomarkers to Enable the Development of Neuroprotective Therapies for Huntington’s Disease , 2011 .

[3]  Geoffrey S. Young,et al.  SUSCEPTIBILITY‐ENHANCED 3‐TESLA T1‐WEIGHTED SPOILED GRADIENT ECHO OF THE MIDBRAIN NUCLEI FOR GUIDANCE OF DEEP BRAIN STIMULATION IMPLANTATION , 2009, Neurosurgery.

[4]  Janet M. Thornton,et al.  Metal-MACiE: a database of metals involved in biological catalysis , 2009, Bioinform..

[5]  M. Wessling-Resnick,et al.  Modulation of intracellular iron levels by oxidative stress implicates a novel role for iron in signal transduction , 2009, BioMetals.

[6]  David H Salat,et al.  Complexity and Heterogeneity: What Drives the Ever‐changing Brain in Huntington's Disease? , 2008, Annals of the New York Academy of Sciences.

[7]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[8]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[9]  Jim Mintz,et al.  Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications , 2007, Neurochemical Research.

[10]  S. Hersch,et al.  Mechanisms of Copper Ion Mediated Huntington's Disease Progression , 2007, PloS one.

[11]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[12]  Koichi Oshio,et al.  Application of k-space energy spectrum analysis to susceptibility field mapping and distortion correction in gradient-echo EPI , 2006, NeuroImage.

[13]  E. Hirsch,et al.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. , 2006, Molecular biology of the cell.

[14]  A. Hamby,et al.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Reichenbach,et al.  Magnetic susceptibility-weighted MR phase imaging of the human brain. , 2005, AJNR. American journal of neuroradiology.

[16]  A. Dale,et al.  Thinning of the cerebral cortex in aging. , 2004, Cerebral cortex.

[17]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[18]  Mark P Mattson,et al.  Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders , 2004, Annals of the New York Academy of Sciences.

[19]  O. Andreassen,et al.  Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease , 2001, Journal of neurochemistry.

[20]  R H Myers,et al.  Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.

[21]  Anders M. Dale,et al.  Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex , 2001, IEEE Transactions on Medical Imaging.

[22]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[23]  E. Siemers,et al.  Rate of functional decline in Huntington’s disease , 2000, Neurology.

[24]  M. Beal,et al.  Oxidative Stress in Huntington's Disease , 1999, Brain pathology.

[25]  Marian DiFiglia,et al.  Huntington Disease , 1998 .

[26]  P. Reber,et al.  Correction of off resonance‐related distortion in echo‐planar imaging using EPI‐based field maps , 1998, Magnetic resonance in medicine.

[27]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[29]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[30]  C. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .